Works by Shpilberg, Ofer

Results: 101
    1

    Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.

    Published in:
    EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.4
    By:
    • Richardson, Paul G.;
    • Nagler, Arnon;
    • Ben-Yehuda, Dina;
    • Badros, Ashraf;
    • Hari, Parameswaran N.;
    • Hajek, Roman;
    • Spicka, Ivan;
    • Kaya, Hakan;
    • LeBlanc, Richard;
    • Sung-Soo Yoon;
    • Kihyun Kim;
    • Martinez-Lopez, Joaquin;
    • Moshe Mittelman;
    • Shpilberg, Ofer;
    • Blake, Paul;
    • Teru Hideshima;
    • Colson, Kathleen;
    • Laubach, Jacob P.;
    • Ghobrial, Irene M.;
    • Leiba, Merav
    Publication type:
    Article
    2
    3
    4

    Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x
    By:
    • Delforge, Michel;
    • Terpos, Evangelos;
    • Richardson, Paul G.;
    • Shpilberg, Ofer;
    • Khuageva, Nuriet K.;
    • Schlag, Rudolf;
    • Dimopoulos, Meletios A.;
    • Kropff, Martin;
    • Spicka, Ivan;
    • Petrucci, Maria T.;
    • Samoilova, Olga S.;
    • Mateos, Maria-Victoria;
    • Magen-Nativ, Hila;
    • Goldschmidt, Hartmut;
    • Esseltine, Dixie-Lee;
    • Ricci, Deborah S.;
    • Liu, Kevin;
    • Deraedt, William;
    • Cakana, Andrew;
    • van de Velde, Helgi
    Publication type:
    Article
    5

    Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x
    By:
    • Dimopoulos, Meletios A.;
    • Mateos, Maria-Victoria;
    • Richardson, Paul G.;
    • Schlag, Rudolf;
    • Khuageva, Nuriet K.;
    • Shpilberg, Ofer;
    • Kropff, Martin;
    • Spicka, Ivan;
    • Palumbo, Antonio;
    • Wu, Ka Lung;
    • Esseltine, Dixie-Lee;
    • Liu, Kevin;
    • Deraedt, William;
    • Cakana, Andrew;
    • Van De Velde, Helgi;
    • San Miguel, Jesús F.
    Publication type:
    Article
    6

    Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: Randomized controlled trial.

    Published in:
    American Journal of Hematology, 2014, v. 89, n. 3, p. 243, doi. 10.1002/ajh.23622
    By:
    • Paul, Mical;
    • Ram, Ron;
    • Kugler, Eitan;
    • Farbman, Laura;
    • Peck, Anat;
    • Leibovici, Leonard;
    • Lahav, Meir;
    • Yeshurun, Moshe;
    • Shpilberg, Ofer;
    • Herscovici, Corina;
    • Wolach, Ofir;
    • Itchaki, Gilad;
    • Bar-Natan, Michal;
    • Vidal, Liat;
    • Gafter-Gvili, Anat;
    • Raanani, Pia
    Publication type:
    Article
    7
    8
    9
    10
    11
    12

    Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41408-020-00357-4
    By:
    • Dimopoulos, Meletios A.;
    • Lonial, Sagar;
    • White, Darrell;
    • Moreau, Philippe;
    • Weisel, Katja;
    • San-Miguel, Jesus;
    • Shpilberg, Ofer;
    • Grosicki, Sebastian;
    • Špička, Ivan;
    • Walter-Croneck, Adam;
    • Magen, Hila;
    • Mateos, Maria-Victoria;
    • Belch, Andrew;
    • Reece, Donna;
    • Beksac, Meral;
    • Spencer, Andrew;
    • Oakervee, Heather;
    • Orlowski, Robert Z.;
    • Taniwaki, Masafumi;
    • Röllig, Christoph
    Publication type:
    Article
    13

    Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.

    Published in:
    Leukemia & Lymphoma, 2010, v. 51, n. 9, p. 1612, doi. 10.3109/10428194.2010.496507
    By:
    • Dreyling, Martin;
    • Hoster, Eva;
    • Bea, Silvia;
    • Hartmann, Elena;
    • Horn, Heike;
    • Hutter, Grit;
    • Salaverria, Itziar;
    • Pott, Christiane;
    • Trneny, Marek;
    • Le Gouill, Steven;
    • Cortelazzo, Sergio;
    • Szymczyk, Michal;
    • Jurczak, Wojciech;
    • Shpilberg, Ofer;
    • Ribrag, Vincent;
    • Hermine, Olivier
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20

    Is Classical Hodgkin's Disease Indeed a Single Entity?

    Published in:
    Leukemia & Lymphoma, 2002, v. 43, n. 9, p. 1813, doi. 10.1080/1042819021000006286
    By:
    • Levy, Amalia;
    • Armon, Yaron;
    • Gopas, Jacob;
    • Ariad, Samuel;
    • Prinsloo, Isebrand;
    • Shpilberg, Ofer;
    • Kapelushnik, Joseph;
    • Sacks, Martin;
    • Benharroch, Daniel
    Publication type:
    Article
    21
    22
    23
    24
    25
    26

    Radiation and Dose‐densification of R‐CHOP in Primary Mediastinal B‐cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial.

    Published in:
    HemaSphere, 2023, v. 7, n. 7, p. e917, doi. 10.1097/HS9.0000000000000917
    By:
    • Held, Gerhard;
    • Thurner, Lorenz;
    • Poeschel, Viola;
    • Ott, German;
    • Schmidt, Christian;
    • Christofyllakis, Konstantinos;
    • Viardot, Andreas;
    • Borchmann, Peter;
    • Engel‐Riedel, Walburga;
    • Frickhofen, Norbert;
    • Nickelsen, Maike;
    • Shpilberg, Ofer;
    • Witzens‐Harig, Mathias;
    • Griesinger, Frank;
    • Krammer‐Steiner, Beate;
    • Neubauer, Andreas;
    • de Nully Brown, Peter;
    • Federico, Massimo;
    • Glass, Bertram;
    • Schmitz, Norbert
    Publication type:
    Article
    27
    28
    29
    30

    Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial

    Published in:
    British Journal of Haematology, 2011, v. 153, n. 2, p. 212, doi. 10.1111/j.1365-2141.2011.08569.x
    By:
    • Richardson, Paul;
    • Schlag, Rudolf;
    • Khuageva, Nuriet;
    • Dimopoulos, Meletios;
    • Shpilberg, Ofer;
    • Kropff, Martin;
    • Vekemans, Marie-Christiane;
    • Petrucci, Maria Teresa;
    • Rossiev, Viktor;
    • Hou, Jian;
    • Robak, Tadeusz;
    • Mateos, Maria-Victoria;
    • Anderson, Kenneth;
    • Esseltine, Dixie-Lee;
    • Cakana, Andrew;
    • Liu, Kevin;
    • Deraedt, William;
    • van de Velde, Helgi;
    • San Miguel, Jesús F.
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim–Chester Disease.

    Published in:
    Cancers, 2020, v. 12, n. 11, p. 3240, doi. 10.3390/cancers12113240
    By:
    • Weissman, Ran;
    • Diamond, Eli L.;
    • Haroche, Julien;
    • Pillar, Nir;
    • Shapira, Guy;
    • Durham, Benjamin H.;
    • Buthorn, Justin;
    • Cohen, Fleur;
    • Ki, Michelle;
    • Stemer, Galia;
    • Ulaner, Gary A.;
    • Amoura, Zahir;
    • Emile, Jean-François;
    • Mazor, Roei D.;
    • Shomron, Noam;
    • Abdel-Wahab, Omar I.;
    • Shpilberg, Ofer;
    • Hershkovitz-Rokah, Oshrat
    Publication type:
    Article
    45
    46
    47
    48
    49
    50